Log in with your email address username.

×

Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

[Correspondence] Oseltamivir for influenza – Authors’ reply

We thank the correspondents for their interest in our study.1 We did our meta-analysis of oseltamivir treatment studies in view of the controversy that has arisen about oseltamivir’s rational use. To us, an analysis with the most robust design, namely an individual patient data analysis, would help clarify issues of importance not only to clinicians but also to public health decision makers. We generally agree with Peter Doshi and colleagues who concluded that the overall results were not strikingly different from their meta-analysis, which used data obtained from study reports alone.

email